Center for Translational Research AB acquires Admescope’s Swedish operation (changing name to Metasafe) and strengthens collaboration with Admescope and Symeres.
Center for Translational Research CTR is a group of complementary life science service companies providing expert services and advice within product development. The services provided by Admescope Sweden/Metasafe complements well the current offerings and will contribute to a more seamless development process bringing value for customers, states CTR in a press release.
“Through the transfer of Admescope Sweden/Metasafe to our group we will be able to offer a more integrated approach and develop the services for our customers using the talented staff and facilities in the human metabolite profiling and characterization area. We look forward to the collaboration with Admescope and Symeres, aiming for a more complete solution for several projects,” said Karin Meyer, CEO at CTR, in the press release.
The activities will continue without interruption and with the same staff, in the same facilities, using the same instrumentation, states CTR. Johanna Haglund, Business Development Scientist and Head of Safety Metabolism will lead the team.
“We look forward to continued collaborations with the CTR group and are pleased that our talented MIST-team has a new home where it fits into the clinical drug development landscape.”
“Admescope, as part of Symeres, continues to focus on delivering tailored solutions in non-clinical ADME support and toxicology, with strategic investments to further expand our services in these areas globally. We look forward to continued collaborations with the CTR group and are pleased that our talented MIST-team has a new home where it fits into the clinical drug development landscape,” said Outi Kontkanen, CEO Admescope, in the press release.
“With this transfer we will have a very logical consolidation of our ADME services at two sites, namely Nijmegen in the Netherlands and Oulu in Finland which allows us to focus our development investments. Symeres looks forward to further collaboration with CTR which will strengthen our access to key competences and techniques in pre-clinical development,” said Symeres CEO Eelco Ebbers, in the press release.
Photo of Karin Meyer: Margareta Bloom Sandbaeck